Please provide your email address to receive an email when new articles are posted on . The researchers added that, “subsequently, [biosimilar adalimumab] effectiveness and safety were proved in two ...

The U.S. Food and Drug Administration (FDA) approved Novartis' (NYSE:NVS) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira.

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). Sandoz ...

Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

On March 21, 2023, Sandoz, announced FDA approval of its citrate-free high-concentration formulation (HCF) of its biosimilar HYRIMOZ® (adalimumab-adaz) injection. HYRIMOZ® is approved to treat seven ...

Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the ...

Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...

(Reuters) -Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Sandoz said that ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, ...